Results 51 to 60 of about 4,881 (174)

Patient‐derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma

International Journal of Cancer, Volume 157, Issue 4, Page 760-772, 15 August 2025.
What's new? Only about one‐fifth of patients with pancreatic ductal adenocarcinoma (PDAC) qualify for curative treatment approaches employing adjuvant chemotherapy. Tools to predict PDAC response to chemotherapeutic regimens, however, are lacking.
Christine Nitschke, Charline Phan, Yara Souto, Philipp Walter, Mara Goetz, Gediminas Simkus, Jacob Thastrup, Ronald Simon, Jürgen Kupper, Jakob Izbicki, Steven A. Johnsen, Thilo Hackert, Marianne Sinn, Harriet Wikman, Faik G. Uzunoglu, Tabea M. Sturmheit   +15 more
wiley   +1 more source

Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma

British Journal of Pharmacology, Volume 182, Issue 16, Page 3903-3922, August 2025.
Abstract Background and Purpose Immune checkpoint inhibitors, such as anti­PD1, revolutionized melanoma treatment. However, resistance and low response rates remain problems. Our goal was to pinpoint actionable biomarkers of resistance to anti‐PD1 treatment and verify therapeutic effectiveness in vivo.
Szonja Anna Kovács, Tamás Kovács, András Lánczky, Ágnes Paál, Zsombor I. Hegedűs, Nabil V. Sayour, Lilla Szabó, Andrea Kovács, Giampaolo Bianchini, Péter Ferdinandy, Alberto Ocana, Zoltán V. Varga, János Tibor Fekete, Balázs Győrffy   +13 more
wiley   +1 more source

MS275 Inhibits Neuroblastoma Cell Growth by Mediating H3K27ac/PROX1 Axis In Silico and In Vitro

The FASEB Journal, Volume 39, Issue 13, 15 July 2025.
Our study demonstrates that MS275, a selective HDAC inhibitor, suppresses HDAC1/3 protein expression, leading to hyperacetylation of histone H3 at lysine 27 (H3K27ac) within the PROX1 promoter region (−608 to −508). This epigenetic modification upregulates PROX1 transcription, which subsequently modulates key cellular processes, including cell cycle ...
Chao Yuan, Chaoqun Li, Junwei Lu, Shengjie Liao, Runkun Wu, Duanzhuo Li, Mi Huang, Dacong Gong, Weibin Wu, Xin Yu, Shinuan Fei, Wenxia Si   +11 more
wiley   +1 more source

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

FEBS Open Bio, Volume 15, Issue 7, Page 1159-1175, July 2025.
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli, Andrea Spinaci, Cui Chang, Rosaria Volpini, Catia Lambertucci, Matteo Landriscina, Vincenza Conteduca, Consuelo Amantini, Cristina Aguzzi, Laura Zeppa, Martina Giangrossi, Laura Soverchia, Matteo Santoni, Massimo Nabissi, Giorgio Santoni, Carlo Polidori   +15 more
wiley   +1 more source

STOX1 Isoform A Promotes Proliferation and Progression of Hepatocellular Carcinoma by Dual Mechanisms of Transcriptionally Upregulation of Cyclin B1 and Activation of ROS‐Dependent PTEN/AKT1 Signaling

Cancer Medicine, Volume 14, Issue 13, July 2025.
ABSTRACT Background Dysregulation of transcription factors is one of the most common factors for the pathogenesis of hepatocellular carcinoma (HCC). To the best of our knowledge, no study has yet investigated the clinical significance and functional role of STOX1 in HCC. Methods Real‐time PCR, Western blotting and immunohistochemistry were performed to
Chunlin Jiang, Chong Wang, Jian Ao, Yangping Liu, Fengjie Sun, Wangpan Shi, Zeyi Guo, Yanping Wu, Luxiang Gan, Meimei Wu, Yaofeng Zhi, Zijie Meng, Wanting Wu, Juanhua Wu, Yong Ye, Xin Zhang, Dong Ren, Mingxin Pan   +17 more
wiley   +1 more source

Recent Cutting‐Edge Technologies for the Delivery of Peptide Nucleic Acid

Chemistry – A European Journal, Volume 31, Issue 34, June 17, 2025.
This review provides an overview of PNA cellular delivery methods, starting with traditional peptide‐based systems and progressing to advanced approaches using nanoparticles, liposomes, and calixarene. It highlights how these innovative strategies have opened the way for more effective and efficient PNA delivery, ultimately enhancing the potential for ...
Concetta Avitabile, Maria Teresa Cerasa, Antonia D'Aniello, Michele Saviano, Maria Moccia   +4 more
wiley   +1 more source

Crystalline forms of bovine pancreatic ribonuclease. Some new modifications [PDF]

, 1962
Margaret King, Jake Bello, E. H. Pignataro, David Harker   +3 more
openalex   +1 more source

The active site and mechanism of action of bovine pancreatic ribonuclease. 5. The charge types at the active centre [PDF]

, 1962
Dorothy Findlay, AP Mathias, B. R. Rabin
openalex   +1 more source

The active site and mechanism of action of bovine pancreatic ribonuclease. 6. Kinetic and spectrophotometric investigation of the interaction of the enzyme with inhibitors and p-nitrophenyl acetate [PDF]

, 1962
CA Ross, AP Mathias, B. R. Rabin
openalex   +1 more source

The exo- or endonucleolytic preference of bovine pancreatic ribonuclease A depends on its subsites structure and on the substrate size [PDF]

, 2002
Claudi M. Cuchillo
openalex   +3 more sources